Showing 8081-8090 of 8695 results for "".
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull
- May 26, 2017 is Don't Fry Dayhttps://practicaldermatology.com/news/may-26-2017-is-dont-fry-day/2458173/The Friday before Memorial Day (May 26, 2017) is Don’t Fry Day. The day, designated by the American Society for Dermatologic Surgery Association (ASDSA) in collaboration with
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Statement from AAD President Henry W. Lim, MD, FAAD, on the Safety of Sunscreenhttps://practicaldermatology.com/news/statement-from-aad-president-henry-w-lim-md-faad-on-the-safety-of-sunscreen/2458179/“The American Academy of Dermatology wants to emphasize that sunscreen remains a safe, effective form of sun protection. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cance
- RCM Imaging of Skin Granted Reimbursement Codes by CMS; Wider Adoption Likelyhttps://practicaldermatology.com/news/rcm-imaging-of-skin-granted-reimbursement-codes-by-cms/2458187/After more than two decades of effort, reflectance confocal microscopy (RCM) imaging of skin has been granted reimbursement codes by the US Centers for Medicare and Medicaid Services. A report in Lasers in Sur
- CURAD Launches CURAD SoothePlus with ARM & HAMMER Baking Soda for Enhanced Wound Carehttps://practicaldermatology.com/news/curad-launches-curad-sootheplus-with-arm-hammer-baking-soda-for-enhanced-wound-care/2458191/CURAD® is
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re
- La Roche-Posay Supports Oncodermatology Clinic at George Washington Universityhttps://practicaldermatology.com/news/la-roche-posay-supports-oncodermatology-clinic-at-george-washington-university/2458196/
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- Paratek: Phase 3 Data Show Omadacycline Effective Against Common Skin Pathogens, Including MRSAhttps://practicaldermatology.com/news/paratek-phase-3-data-show-omadacycline-effective-against-common-skin-pathogens-including-mrsa/2458211/Analysis of microbiology data from a Phase 3 study of omadacycline in acute skin infections shows that once-daily treatment with IV-to-oral omadacycline is effective in treating the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant S